CAR-T biotech Caribou weighs its options after struggling to find funding
vispa-celNegative
AI Analysis
Summary
Caribou Biosciences is discontinuing two allogeneic CAR-T cell therapy programs, including vispa-cel, and planning to exit the business after failing to secure funding to continue operations.
Outcome Details
Company discontinuing allogeneic CAR-T programs and planning exit due to failed funding efforts
Importance:8/10
Sentiment:
-0.95
CAR-Tallogeneicprogram discontinuationfunding failurecompany exit
Related Companies
Read the original article
Published by Endpoints News on October 7, 2026 11:17 AM